Colorectal cancer (CRC), the second most common cancer globally, resulted in 881,000 deaths in 2018. Toll-like receptors (TLRs) are crucial to detecting pathogen invasion and inducing the host's immune response. This study aimed to explore the prognostic value of TLR2 and TLR4 tumor expressions in colorectal cancer patients. We studied the immunohistochemical expressions of TLR2 and TLR4 using tissue microarray specimens from 825 patients undergoing surgery in the Department of Surgery, Helsinki University Hospital, between 1982 and 2002. We assessed the relationships between TLR2 and TLR4 expressions and clinicopathological variables and patient survival. We generated survival curves using the Kaplan-Meier method, determining significance with the log-rank test. Among patients with lymph node-positive disease and no distant metastases (Dukes C), a strong TLR2 immunoactivity associated with a better prognosis (p < 0.001). Among patients with local Dukes B disease, a strong TLR4 immunoactivity associated with a worse disease-specific survival (DSS; p = 0.017). In the multivariate survival analysis, moderate TLR4 immunoactivity compared with strong TLR4 immunoactivity (hazard ratio (HR) 0.66, 95% confidence interval (CI) 0.49-0.89, p = 0.007) served as an independent prognostic factor. In the multivariate analysis for the Dukes subgroups, moderate TLR2 immunoactivity (HR 2.63, 95% CI 1.56-4.44, p < 0.001) compared with strong TLR2 immunoactivity served as an independent negative prognostic factor in the Dukes C subgroup. TLR2 and TLR4 might be new prognostic factors to indicate which CRC patients require adjuvant therapy and which could spare from an unnecessary follow-up, but further investigations are needed.

中文翻译：

---

组织TLR2和TLR4在结直肠癌中的预后作用。

大肠癌（CRC）是全球第二大最常见的癌症，2018年导致881,000人死亡。Toll样受体（TLR）对于检测病原体入侵和诱导宿主的免疫反应至关重要。这项研究旨在探讨TLR2和TLR4肿瘤表达在大肠癌患者中的预后价值。我们使用1982年至2002年在赫尔辛基大学医院外科的825例接受手术的患者的组织微阵列标本研究了TLR2和TLR4的免疫组织化学表达。我们评估了TLR2和TLR4的表达与临床病理变量和患者生存率之间的关系。我们使用Kaplan-Meier方法生成了生存曲线，并通过对数秩检验确定了显着性。在淋巴结阳性疾病且无远处转移的患者中（Dukes C），强大的TLR2免疫活性与更好的预后相关（p <0.001）。在患有局部Dukes B病的患者中，强大的TLR4免疫活性与较差的疾病特异性生存率相关（DSS； p = 0.017）。在多因素生存分析中，中度TLR4免疫活性与强TLR4免疫活性（危险比（HR）0.66，95％置信区间（CI）0.49-0.89，p = 0.007）相比是独立的预后因素。在Dukes亚组的多变量分析中，中等强度的TLR2免疫活性（HR 2.63，95％CI 1.56-4.44，p <0.001）与强烈的TLR2免疫活性相比，是Dukes C亚组的独立阴性预后因素。